Also, a meta-analysis conducted by Wang et al. previously showed that SGLT2i decreased the levels of CRP, ferritin, and leptin of patients with type 2 diabetes mellitus, when compared to placebo or standard antidiabetic medication [18]. This evidence concerns the gene CRP and type 2 diabetes mellitus.